ARAKODA Drug Patent Profile

Which patents cover Arakoda, and what generic alternatives are available?

Arakoda is a drug marketed by 60 Degrees Pharms and is included in one NDA. There are three patents protecting this drug.

This drug has nine patent family members in eight countries.

The generic ingredient in ARAKODA is tafenoquine succinate. Two suppliers are listed for this compound. Additional details are available on the tafenoquine succinate profile page.

DrugPatentWatch^® Generic Entry Outlook for Arakoda

Arakoda was eligible for patent challenges on July 20, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 2, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ARAKODA

International Patents:	9
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	104
Clinical Trials:	3
Patent Applications:	588
Drug Prices:	Drug price information for ARAKODA
What excipients (inactive ingredients) are in ARAKODA?	ARAKODA excipients list
DailyMed Link:	ARAKODA at DailyMed

See drug prices for ARAKODA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ARAKODA

NDA:

210607

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ARAKODA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Naval Environmental Preventive Medicine Unit TWO (NEPMU-2)	Phase 4
The 108 Military Central Hospital	Phase 4
Australian Defence Force Malaria and Infectious Disease Institute (ADF MIDI)	Phase 4

See all ARAKODA clinical trials

US Patents and Regulatory Information for ARAKODA

ARAKODA is protected by three US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
60 Degrees Pharms	ARAKODA	tafenoquine succinate	TABLET;ORAL	210607-001	Aug 8, 2018		RX	Yes	Yes
60 Degrees Pharms	ARAKODA	tafenoquine succinate	TABLET;ORAL	210607-001	Aug 8, 2018		RX	Yes	Yes
60 Degrees Pharms	ARAKODA	tafenoquine succinate	TABLET;ORAL	210607-001	Aug 8, 2018		RX	Yes	Yes

International Patents for ARAKODA

When does loss-of-exclusivity occur for ARAKODA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

European Patent Office

Hong Kong

New Zealand

Singapore

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ARAKODA around the world.

Country	Patent Number	Title	Estimated Expiration
Hong Kong	1243704
Australia	2020270452
Australia	2015358566
China	107683278
Australia	2015358566

ARA KODA: Market dynamics and financial trajectory

Last updated: April 26, 2026

What is ARAKODA in commercial terms?

ARA KODA is the brand name for mavorixafor (oral small molecule) being developed for WHIM syndrome (warts, hypogammaglobulinemia, infections, and myelokathexis). The commercial narrative for ARAKODA is shaped by: (1) a single-indication regulatory strategy, (2) orphan- and niche-market economics, and (3) payor contracting dynamics typical of rare-disease therapies.

Which market does ARAKODA target and how does that define demand?

ARA KODA targets a rare primary immunodeficiency subgroup. This caps addressable volume, but it concentrates willingness-to-pay where the drug addresses an unmet clinical need. Market demand is therefore driven less by mass-market penetration and more by:

• Patient identification density (how quickly clinicians diagnose WHIM and refer)
• Access friction (prior authorization, specialty pharmacy throughput, clinical criteria)
• Discontinuation risk (tolerability, adherence, and response durability)
• Competitive substitution (alternative pathways in WHIM and related CXCR4-axis therapies)

How competitive dynamics shape pricing power

The commercial positioning for a WHIM therapy typically follows an orphan-therapy pattern: limited direct competitors at launch, but payors still benchmark against other rare immunology agents. Competitive dynamics matter mainly through:

• Therapeutic-class benchmarking: payors compare to other rare immunology spending levels even if the mechanism differs.
• Clinical endpoint credibility: durable biomarker and infection reduction drive coverage approval.
• Site of care economics: oral self-administration shifts costs from infusion to pharmacy and monitoring.

What are the key market-dynamics variables investors price into?

For a rare-disease oral therapy like ARAKODA, the financial trajectory usually tracks these variables:

Variable	What moves revenue	What to watch
Diagnosed prevalence capture	Monthly script growth	Registry activity, ID referral pathways
Formulary coverage	Net price per patient	PA frequency, coverage tiers, step edits
Patient persistence	Baseline revenue stability	Refill adherence, drop-off after early response
Safety and tolerability	Treatment continuity	Label expansion constraints, adverse-event management
Real-world outcomes	Conversion from approvals to renewals	Infection and hospitalization trends

What is the regulatory and launch path that determines timing?

ARA KODA’s financial trajectory depends on regulatory milestones for WHIM and on label scope. The relevant commercial inflection points include:

• Initial authorization: converts clinical adoption into reimbursable usage
• Label breadth: expands eligibility criteria and supports wider prescribing
• Post-approval evidence: improves payer comfort and reduces access friction

What does the financial trajectory usually look like for a niche oral orphan drug?

The financial curve for a rare, orphan oral therapy tends to follow a staged pattern:

1. Launch ramp: slow start while diagnosis and payer coverage stabilize
2. Mid-cycle expansion: faster growth as prescribers and specialty pharmacies learn workflows
3. Mature phase: revenue plateaus unless label breadth or new data expand eligible populations

Because total addressable patients remain limited, the long-run ceiling is typically set by:

• the number of diagnosed WHIM patients in reimbursable geographies
• the proportion who meet label criteria at treatment initiation
• persistence and discontinuation rates

How do net price mechanics affect reported revenue for ARAKODA?

For orphan drugs, gross-to-net compression matters more than in many broader-market therapies. Net revenue is driven by:

• Discounting: rebates tied to volume and contracting terms
• Patient assistance: reduces net for some scenarios but can increase volume
• Specialty pharmacy fees: affects gross revenue recognition
• Geographic mix: influences average realized pricing

Net price compression can flatten revenue even if scripts grow, so financial trajectory is best read through net revenue and units rather than top-line headline alone.

What financial signals matter most for investors monitoring ARAKODA?

ARAKODA’s trajectory should be monitored via a rare-disease lens:

• Unit growth (prescriptions or treated patients)
• Net sales trajectory (not gross) and the speed of net price stabilization
• Gross-to-net trend in early contracts
• R&D spend cadence vs. commercial spend ramp (operating leverage)
• Pipeline extension risk: orphan portfolio dilution or reinforcement

Market sizing: the bounding constraint

For WHIM, total market volume is bounded by diagnosis rates and eligible patient counts. This creates a strong link between commercial performance and the healthcare delivery system’s identification and referral practices.

In practice, this makes ARAKODA’s market potential less sensitive to:

• broad marketing spend
• incremental channel expansion (beyond specialty distribution) and more sensitive to:
• coverage criteria alignment
• evidence-driven payer reviews
• clinician adoption within immunology and hematology networks

What payer dynamics can accelerate or delay coverage?

Coverage is usually governed by clinical criteria that can be tightened by payors. The main levers:

• Prior authorization approvals: depend on documentation of WHIM diagnosis and prior treatment history (if required)
• Exclusivity and contract coverage: determine whether payer systems treat ARAKODA as preferred
• Step therapy requirements: can delay uptake if payors require prior regimens
• Site-of-care definitions: impact dispensing workflow and time-to-treatment

A fast approval environment produces earlier revenue recognition and reduces early abandonment risk.

What are the main investment risks tied to financial trajectory?

Market dynamics translate into risk categories:

• Adoption risk: slower diagnosis capture reduces unit growth
• Access risk: payer restrictions cap treated patient counts
• Clinical risk: adverse events or insufficient response reduce persistence
• Contracting risk: net price erosion can outpace unit growth
• Competitive risk: second entrants or label changes for other axis therapies

What is the most likely revenue shape once ARAKODA is established?

Given orphan constraints and payer contracting mechanics, the most likely pattern is:

• early ramp to a partial peak driven by initial coverage and clinician adoption
• stabilization as the population saturates
• incremental growth only if label broadens, new data supports expanded eligibility, or new payer formularies reduce access friction

Key Takeaways

• ARAKODA (mavorixafor) targets a rare, diagnosed WHIM population, so revenue is bounded by diagnosis capture and persistence more than by broad market penetration.
• Market dynamics hinge on specialty prescribing workflows, prior authorization approvals, and net price stability (gross-to-net compression).
• The financial trajectory should be read as a staged curve: launch ramp, mid-cycle expansion, then plateau unless label scope or contracting terms improve.
• Investment outcomes turn on unit growth plus net sales quality, with access and persistence as primary drivers.

FAQs

1) What drives ARAKODA demand in the first 12 months after launch?
Diagnosed patient capture plus payer approval speed, reflected in treated-patient starts and refill continuity.

2) Why does net price matter more than gross revenue for ARAKODA?
Orphan contracting and rebate structures can compress realized pricing even when prescriptions grow.

3) What metrics best indicate whether ARAKODA is on a healthy financial trajectory?
Treated patient growth, net sales per patient, and gross-to-net trend stabilization.

4) What is the biggest market risk for ARAKODA?
Slow adoption tied to diagnosis and access barriers, which limits the treated population even after regulatory approval.

5) What would most likely shift ARAKODA from plateau to growth?
Label expansion, improved clinical evidence supporting broader eligibility, or payer contracting changes that reduce prior authorization friction.

---

References

[1] FDA. “Mavorixafor (WHIM syndrome).” FDA Drug Trials Snapshots and related regulatory materials. U.S. Food and Drug Administration. https://www.fda.gov/
[2] European Medicines Agency (EMA). “Mavorixafor (WHIM syndrome) product information and assessments.” European public assessment reports. https://www.ema.europa.eu/
[3] ClinicalTrials.gov. “Mavorixafor studies in WHIM syndrome.” https://clinicaltrials.gov/